Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 1 - 10 of 333

<< Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next >>

Last updated: 20th February 2008

Patent No.: WO 144613
Antimicrobial topical composition comprising hyaluronic acid.
Applicant: Mastrodonato M (2007)
A compn. comprising hyaluronic acid or a pharmaceutically acceptable salt thereof for the manuf. of a topical medicament for antimicrobial treatment of the skin or mucosa is described. The compn. addnl. comprises one or more plant exts. with antimicrobial activity. The topical medicament stimulates beta-defensin 2 prodn. in human keratinocytes. Thus, a cream for topical use contained lactoferrin 0.50, sodium hyaluronate 0.50, Arnica montana 0.50, Artemisia vulgaris 0.50, Sambucus nigra 0.50, Piper betel 0.50, ethylhexyl palmitate 10.00, cetearyl alc.-PEG 20 stearate 9.00, Olus 5.00, cetearyl alc. 2.00, glycerin 2.00, dimethicone 1.00, fenossiethanol 0.70, imidazolidinyl urea 0.30, propylparaben 0.15, methylparaben 0.15, disodium EDTA 0.10, and water 66.60%, resp.

Patent No.: WO 142542
Cationic milk proteins for the treatment of bovine mastitis.
Applicant: Bragger JM (2007)
The invention discloses a treatment compn. for treating or preventing bovine mastitis, the treatment compn. characterized in that it includes at least two components which have an isoelec. point of or above substantially 6.8 and is extd. from milk or a milk-derived substance.

Patent No.: WO 136159
Sphingosylphosphorylcholine antagonist for restoration of antimicrobial peptides.
Applicant: Kim HJ, Kim H, Sung KS, Kim D-K, Sung D-S, Park JH, Cho SA, Kim KM, Lee C-H, Kim JJ (2007)
Sphingosylphosphorylcholine (SPC) suppresses the expression of human beta defensins (HBD-1, HBD-2, HBD-3 and HBD-4), cathelicidin (LL-37), and dermcidin in atopic dermatitis patients, and accordingly, SPC antagonists are useful for preventing and treating disorders related to the decreased expression of antimicrobial peptides. SPC dose-dependently decreased antimicrobial peptides in human keratinocytes and in the skin of ICR mice.

Patent No.: WO 133373
TNF-alpha vaccine for treating disease conditions mediated by pathological TNF-alpha.
Applicant: England RL (2007)
It has previously been demonstrated that fusion proteins comprising a native defensin or native chemokine fused to a tumor antigen or viral antigen can elicit an immune response against the tumor antigen or viral antigen. The present invention provides fusion compositions comprising a defensin or chemokine operably linked to a TNFalpha polypeptide and their use in inducing an anti-TNFalpha immune response to counteract disease conditions mediated by pathological presence of TNFalpha, including but not limited to, chronic pain, chronic inflammatory conditions, insulin resistance, diabetes, hypertriglyceridemia, hypercholesterolemia, and atherosclerosis.

Patent No.: WO 126392
Antimicrobial peptides which are linear analogs of human beta-defensin 3 (hBD3).
Applicant: Beuerman R, Zhou L, Liu S, Li J, Suresh A, Verma CS, Tan D (2007)
The invention provides at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, the invention provides a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.

Patent No.: WO 110678
Neutralizing antibodies for Toll-like receptor 4/MD-2 complex.
Applicant: Elson G, Leger O (2007)
The authors disclose the prepn. and characterization of monoclonal antibodies that recognize the Toll-like receptor 4/MD-2 complex and monoclonal antibodies that recognize TLR4 when not complexed with MD-2. In one example, humanized antibodies to TLR4/MD-2 complex inhibit lipopolysaccharide-induced interleukin-6 prodn. by human peripheral blood leukocytes.

Patent No.: WO 109750
Fermentation processes.
Applicant: Deinhammer R, Festersen RM (2007)
The present invention provides a fermentation process for producing a fermentation product from starch-containing material wherein one or more antibacterial agents are added before and/or during fermentation. The defensin tested is plectasin, derived from the ebony cup fungus Pseudoplectania nigrella.

Patent No.: WO 087557
Surface-layer protein coated microspheres.
Applicant: De Leeuw EPH, Lu W (2007)
The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes methods of making and using the surface-layer protein coated microspheres of the invention for administering therapeutic agents to a subject in need thereof. Pharmaceutical dosage units that include the surface-layer protein coated microspheres of the invention are included. Various labeled defensins for use in the study of the properties and actions of defensins, and further includes the use of defensins, particularly HD5alpha in the treatment of inflammatory conditions of the bowel, such as Crohn's disease are also included. S-layer coated biodegradable microcapsules (polylactide-co-glycolide) contg. human defensin 5alpha are prepd.

Patent No.: WO 087131
Peptide prodrugs.
Applicant: Denmeade SR, Aggarwal S (2007)
Provided herein are a novel class of oligopeptides and prodrugs that include amino acid sequences contg. cleavage sites for fibroblast activation protein (FAP). Also provided herein are methods of treating FAP related disorders, including cancer.

Patent No.: WO 081487
Production of human alpha-defensins in plant cells as antibiotic for wound and skin care and in treatment of irritable bowel disease, ulcerative colitis and Crohn's disease.
Applicant: Huang N, Zhang D (2007)
The present invention relates, generally, to the prodn. of human defensins including human alpha defensins 1-6 in plant cells, particularly in rice. The method of producing a defensin in plant seeds comprises transforming a plant cell with a chimeric gene comprising a maturation-specific protein promoter from a plant linked to a seed storage protein gene operably linked to seed-specific signal sequence capable of targeting the seed storage protein to seed endosperm and a human defensin gene linked to the seed storage protein gene. Rice plant cells are transformed with the chimeric gene encoding N-terminal signal sequence, seed storage protein and alpha-defensin and plants are grown for a sufficient time to produce seeds contg. the defensin, followed by harvesting the seeds from the plant. The one or more human defensins can be recombinantly-produced and purified from the plant cells and used as an anti-infective agent in wound treatment and skin care or in treatment of intestinal diseases including irritable bowel disease (IBD), ulcerative colitis, and Crohn's disease. The recombinantly-produced alpha-defensins can be provided as oral and topical formulations.